Harrow Health Inc (HROW)vsTeva Pharma Industries Ltd ADR (TEVA)
HROW
Harrow Health Inc
$36.35
+3.27%
HEALTHCARE · Cap: $2.01B
TEVA
Teva Pharma Industries Ltd ADR
$29.46
+1.10%
HEALTHCARE · Cap: $33.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 6802% more annual revenue ($17.26B vs $250.04M). TEVA leads profitability with a 8.2% profit margin vs -2.0%. TEVA earns a higher WallStSmart Score of 73/100 (B).
HROW
Hold37
out of 100
Grade: F
TEVA
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HROW.
Margin of Safety
+39.4%
Fair Value
$56.63
Current Price
$29.46
$27.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 45.4% year-over-year
Strong operational efficiency at 20.6%
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.3%
Earnings expanding 40.0% YoY
Generating 1.0B in free cash flow
Areas to Watch
Trading at 28.6x book value
ROE of -9.6% — below average capital efficiency
Earnings declined 64.0%
Currently unprofitable
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : HROW
The strongest argument for HROW centers on Revenue Growth, Operating Margin. Revenue growth of 45.4% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bear Case : HROW
The primary concerns for HROW are Price/Book, Return on Equity, EPS Growth.
Bear Case : TEVA
The primary concerns for TEVA are Altman Z-Score.
Key Dynamics to Monitor
HROW profiles as a hypergrowth stock while TEVA is a value play — different risk/reward profiles.
TEVA carries more volatility with a beta of 0.72 — expect wider price swings.
HROW is growing revenue faster at 45.4% — sustainability is the question.
TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (73/100 vs 37/100) and 11.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Harrow Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?